Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
300p ask now
Year high of 420 about to be taken out
US biotech will be all over this - possible takeover?
29 mill float could get difficult to buy
This is massive news!!!
coming in - holding it back soon will be let go I am sure
wait until people wake up
this is massive news!!!
Only company in the world who can detect both antibodies in one 30 min test!!!!! So you know if infection was recently or historic
This sounds pretty explosive to me - another pharma about to take off?
So its been about a month that the antibody test was ready. It doesnt look like there is a rush by the UK govt to rollout the antibody test just yet, but I would have expected some take-up nontheless. Anyone has a view of when a sales update can be expected and what potential numbers will truly take it upwards given that sales this year on other diagnostics for IDH have been 80% of last year due to covid and I presume will be pretty flat still.
23rd Jul 2020 7:00 am RNS AGM Statement
" ... COVID-19 Testing Range
As announced on 30 June, we released our automated SARS-Cov2-IgG test in countries that accept the CE mark. Interest from our direct and distribution customers has been strong and initial feedback from their validation processes positive. The first sales of this test were made during July. We are hoping to launch a complimentary SARS-Cov2-IgM automated test in the coming months. Furthermore, we are also providing contract manufacturing services to a developer of an ELISA based test, and produced the first prototype batches in June and July.
These products have great potential, though it is too early to estimate the revenue levels which they will generate. We are confident IDS have enough capacity for analyser instruments and assay manufacturing to meet likely demand. ..."
https://www.lse.co.uk/rns/IDH/agm-statement-tfwz3df1tkdvv99.html
A lot of buy have been showing as sells.
And your philosophy is precisely why many investors buy high and sell low, rather than the opposite.
Nobody had bought this share since last update on the 30th June which has resulted in share price falling by 15% since last RNS update. Not looking like a very good investment at the moment.
A comparison to some other COVID-19 testing plays shows how undervalued IDH is:
RENX 560p, market cap. £333M.
AVCT 131p, market cap. £249M.
IDH at 265p is valued at just £78M.
However, it's still relatively early days, and I'm confident that this disparity will be corrected in due course.
A key should be sales news, and I'm confident that there will be enormous uptake for IDH's offering.
Thanks for the very informative posts here. As has already been posted here there are solid reasons to invest in IDH at the moment especially with their with their unique quanttiative assay anti body test now available on the commercial market. However, it seems that that this is still to be reflected in the actual share activity which is very low at the moment with most buys only coming when news hits the market. A nice consolidation of the share price between any actual news would therefore be very welcome here. Any other thoughts?
Well done and thanks to IDH's management for launching this COVID-19 antibody test bang on schedule, and for keeping the market so well updated.
They look to have played an absolute blinder here in launching this 'platinum standard test' that could be a 'licence to print money'.
And at just 270p IDH still isn't at much of a premium to the 240p+ that it was at for most of the spring, despite this game-changing development from the company.
Though I would expect that to change over time.
30th Jun 2020 7:00 am RNS Launch of assay to detect SARS-CoV-2 antibodies
"Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces that following the announcement on 12 June, our fully automated SARS-CoV-2 IgG antibody test ("the Test") will be available for sale from today.
The test can now be purchased by customers in the UK, the EU, and a number of other countries which accept the CE mark as the basis of regulatory approval. We have commenced the process of working with various national reference centers and governmental bodies to ensure a roll-out according to national guidelines.
Jaap Stuut, CEO of IDS commented
"We are pleased to announce the release to the market of our automated SARS -CoV-2 antibody test, running on the IDS-iSYS analyser. IDS will now seek to commercialise this test via our direct sales force in Europe, and through our extensive distribution network elsewhere, and we look forward to joining the efforts to minimise the impact of the COVID-19 virus."
About the Test
The Test, which arises from the partnership between IDS and Technogenetics, is designed to run on the installed base of over 600 automated IDS-iSYS analysers. The Test:
· Detects specific IgG antibodies indicating past exposure to the COVID-19 virus and immune response;
· Is a quantitative test which determines antibody concentration (titer);
· Is highly accurate with a sensitivity of 100% and a specificity of 99.4%;
· Provides Test results available within 25 minutes.
Unlike many COVID-19 serology assays currently available, this Test is a quantitative assay, thus it can determine the antibody concentration in patient serum. Although the clinical level of functional immunity conferred by SARS-CoV-2 IgG antibodies has not yet been determined, we believe quantitative tests may ultimately be valuable in determining immunity status based on the levels of antibody in the blood.
All steps of the Test are automated with no manual reagent preparation required, ensuring minimal hands-on time for lab staff and a high daily throughput."
https://www.lse.co.uk/rns/IDH/launch-of-assay-to-detect-sars-cov-2-antibodies-8h15g7t29fy3gkf.html
News tomorrow if they said launch and sales by end of June
Stocks being pumped to overvaluations will come down, whereas better value stocks will move up. -
Benjamin Graham:
“In the short run, the market is a voting machine but in the long run, it is a weighing machine.”
HTTP://www.goodreads.com/quotes/831517-in-the-short-run-the-market-is-a-voting-machine
Warren Buffett:
"I would rather be certain of a good result than hopeful of a great one."
HTTP://www.quoteswise.com/warren-buffett-quotes-5.html
At just 240p IDH is looking massively oversold, and nicely poised for a big imminent rebound.
Do have a great deal of confidence in IDH and the fundamentals are excellent. Yes, totally agree, just requires some patience here with sales news due very soon.
It's just a few relatively small retail sales.
Probably from people who bought in after the recent COVID-19 RNS, which means that they would be selling at a loss.
One of the biggest mistakes you can make in investment is impatience in selling out of a good share far too early.
If you have confidence in the IDH story, and its value, then buy, and wait for the market to reflect that.
Just bought in here recently. Why all the sells before news of contracts etc?
Bit of volume starting to come in...I agree that I think we'll see a steady rise here over the rest of the year - certainly back to the £5 range, as there are only 29m shares in issue this still only puts the company at £150m market cap.
IDH is a former 20-bagger.
And it has plenty of facilities and cash to help address the COVID-19 testing shortage.
This could fuel another great period of share price performance.
IDH's current market cap. is £80.6M. at 280p, of which over a third is covered by its cash of about £28M.
And this is a nice market cap. for a growing business to achieve a stellar rating from.
Because tracker funds are forced to buy in as the s.p. and market cap. rise.
This dynamic helped to fuel IDH's stellar rise to over £12 a share about a decade ago.
Thanks to Crabtree for this useful calculation on Friday about the potential revenue capacity from the new IDH-Technogenetics antibody test, which is launching within the next two weeks:
Crabtree Posts: 152 Price: 395.00 No Opinion
RE: game changer Fri 09:35
"read the RNS
600 labs have it and can produce 10k tests per month
6m per month at say £5 a test is £30m revenue - more labs will now also purchase this machine for this test so it will be more than 600 labs having this - some will have more than one"
https://www.lse.co.uk/ShareChat.asp?ShareTicker=IDH&share=Immunodiagnostic-Systems&page=2
£30M. revenue would equate to £360M. of revenue p.a., albeit shared with IDH's partner Technogenetics.
This isn't just 'pie in the sky': NCYT have been manufacturing millions of COVID-19 testing kits per month, and there is clearly huge unmet demand.
And the quality of IDH's antibody test sets it apart as being a unique game changer.
In addition, because IDH is already profitable, with the necessary infrastructure in place, much of any additional revenue will drop straight to the bottom line as profit.
Note also that the Technogenetics initiative is just one of IDH's COVID-19 deals: there are also others, more details on which should be forthcoming in due course.
IDH has a lot going on regarding the massive COVID-19 opportunity, and the company promises to update the market re. any significant developments:
17th Jun 2020 7:00 am RNS Final Results
" ... 7. Outlook
... We are working to manufacture and commercialise CLIA and ELISA tests to detect SARS-CoV-2 antibodies, combining our resources and capabilities with partners who complement our skill set with their virology know-how. A summary of the opportunities we are working on is set out in Jaap's CEO report, and we will update the market via RNS if there is any significant news in this area. ...
Opportunities
We are currently in negotiations with a number of partners to manufacture and commercialise COVID-19 antibody test kits in both ELISA and CLIA formats.
We are currently working to manufacture and commercialise COVID-19 antibody test kits in both ELISA and CLIA formats, combining our resources and capabilities with partners who have knowledge in virology and infectious diseases. Our development partner, Technogenetics, has developed a COVID-19 IgG assay to detect SARS-CoV-2 antibodies. This quantitative automated assay which runs on the IDS-iSYS analyser, should be available for sale by IDS before the end of June, in Europe and distribution regions whose regulatory regime is based on the CE-mark.
In addition, we have agreed commercial terms with a UK based specialist medical diagnostics company to produce components of their COVID-19 ELISA manual assay. Finally, we are working with a number of partners with expertise in virology and immunology to provide a route to market for ELISA-based COVID-19 assays, utilising our direct sales organisation as well as our extensive distribution network. ..."
https://www.lse.co.uk/rns/IDH/final-results-6ttz5pcryfjgpah.html
I think that we can expect some very exciting IDH newsflow over the summer, which should help drive the share price to much higher levels.
Yep - also a very profitable company too in its current form
The appetite will come soon... Maybe one they are producing and selling their tests?
Final results.... Wonder how it will affect the SP today?